Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Giuseppe Saltalamacchia"'
Autor:
Flavia Jacobs, Saverio D’Amico, Elena Zazzetti, Mariangela Gaudio, Chiara Benvenuti, Giuseppe Saltalamacchia, Riccardo Gerosa, Damiano Gentile, Angioletta Lasagna, Paolo Pedrazzoli, Corrado Tinterri, Armando Santoro, Rita De Sanctis, Matteo Della Porta, Alberto Zambelli
Publikováno v:
Digital Health, Vol 10 (2024)
Modern healthcare is experiencing a significant transformation, utilizing technology to improve patient outcomes and make processes more efficient. Breast cancer, being the most commonly diagnosed cancer in women globally, requires innovative approac
Externí odkaz:
https://doaj.org/article/2483bd0708b541b885432a4bb321ae17
Autor:
Raffaella Palumbo, Erica Quaquarini, Giuseppe Saltalamacchia, Alberto Malovini, Pietro Lapidari, Barbara Tagliaferri, Ludovica Mollica, Cristina Maria Teragni, Chiara Barletta, Laura Deborah Locati, Federico Sottotetti
Publikováno v:
Drugs in Context, Vol 13, Pp 1-11 (2024)
Background: Breast cancer is the most frequent tumour worldwide, and the HR+/HER2– subtype is the most common. For this tumour type, endocrine therapy (ET) is the mainstay of treatment. The association of ET and CDK4/6 inhibitors (CDK4/6i) represen
Externí odkaz:
https://doaj.org/article/fb58aea72e3a49eb97cf2df9cc8db001
Autor:
Giuseppe Saltalamacchia, Rosalba Torrisi, Rita De Sanctis, Giovanna Masci, Chiara Miggiano, Mariangela Gaudio, Chiara Benvenuti, Flavia Jacobs, Riccardo Gerosa, Armando Santoro, Alberto Zambelli
Publikováno v:
Biomedicines, Vol 12, Iss 3, p 500 (2024)
Based on the unprecedented results observed in recent clinical trials, antibody-drug conjugates (ADCs) have revolutionized the treatment algorithm of metastatic breast cancer (mBC). The strategy of sequencing different ADCs in other lines of therapy
Externí odkaz:
https://doaj.org/article/e0b0f49af46948a6b9b29eee5d0991ca
Autor:
Rosalba Torrisi, Valentina Vaira, Laura Giordano, Bethania Fernandes, Giuseppe Saltalamacchia, Raffaella Palumbo, Carlo Carnaghi, Vera Basilico, Francesco Gentile, Giovanna Masci, Rita De Sanctis, Armando Santoro
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 3, p 1498 (2024)
We investigated whether we could identify a panel of miRNAs associated with response to treatment in tumor tissues of patients with Hormone Receptor-positive/HER2-negative metastatic breast cancer treated with endocrine therapy (ET) and the CDK4/6 in
Externí odkaz:
https://doaj.org/article/9b5a6ef7c806436c98cecf8f3fc55125
Publikováno v:
Cancer Control, Vol 30 (2023)
Neoadjuvant chemotherapy was originally designed to convert inoperable cancer. Nowadays, this concept has expanded since it can also offer the possibility to evaluate markers of response such as pathological complete response (pCR) with possible impl
Externí odkaz:
https://doaj.org/article/dc61aa7e177e43b2a5eebf414c15f1a6
Autor:
Chiara Benvenuti, Mariangela Gaudio, Flavia Jacobs, Giuseppe Saltalamacchia, Rita De Sanctis, Rosalba Torrisi, Armando Santoro, Alberto Zambelli
Publikováno v:
Biomedicines, Vol 11, Iss 4, p 1083 (2023)
Visceral crisis is a life-threatening clinical condition requiring urgent treatment and accounts for 10–15% of new advanced breast cancer diagnoses, mainly hormone receptor-positive/human epidermal growth factor 2 negative. As its clinical definiti
Externí odkaz:
https://doaj.org/article/43f1e60929b04993a2eb57ac79c56325
Autor:
Raffaella Palumbo, Rosalba Torrisi, Federico Sottotetti, Daniele Presti, Anna Rita Gambaro, Elena Collovà, Antonella Ferzi, Elisa Agostinetto, Cristina Maria Teragni, Giuseppe Saltalamacchia, Barbara Tagliaferri, Emanuela Balletti, Antonio Bernardo, Erica Quaquarini
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: The CDK4/6 inhibitor palbociclib combined with endocrine therapy (ET) has proven to prolong progression-free survival (PFS) in women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastat
Externí odkaz:
https://doaj.org/article/6f5b862879014eec871812b81e941aac
Autor:
Erica Quaquarini, Federico Sottotetti, Francesco Agustoni, Emma Pozzi, Alberto Malovini, Cristina Maria Teragni, Raffaella Palumbo, Giuseppe Saltalamacchia, Barbara Tagliaferri, Emanuela Balletti, Pietro Rinaldi, Costanza Canino, Paolo Pedrazzoli, Antonio Bernardo
Publikováno v:
Journal of Personalized Medicine; Volume 12; Issue 5; Pages: 679
Introduction: Immune checkpoint inhibitors (ICIs) have become the standard of treatment for patients with non-small cell lung cancer (NSCLC). However, there are still many uncertainties regarding the selection of the patient who could benefit more fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::548a8497bf8f6d65ca481075d9a822fc
https://pubmed.ncbi.nlm.nih.gov/35629102
https://pubmed.ncbi.nlm.nih.gov/35629102
Autor:
Chiara Benvenuti, Paola Tiberio, Mariangela Gaudio, Flavia Jacobs, Giuseppe Saltalamacchia, Sebastiano Pindilli, Alberto Zambelli, Armando Santoro, Rita De Sanctis
Publikováno v:
Cancers. 15:1410
Recently, circulating microRNAs (miRNAs) have emerged as potential non-invasive biomarkers for breast cancer (BC) management. In the context of BC patients undergoing neoadjuvant chemotherapy (NAC), the possibility of obtaining repeated, non-invasive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91569b359d0ab305bd744a878e108579
https://doi.org/10.3390/cancers15051410
https://doi.org/10.3390/cancers15051410